WHSL GR 2025: Revolutionizing Obesity Treatment: The Power of GLP-1 Receptor Agonist and Dual GLP-1 / GIP Receptor Agonists Therapies

INSTRUCTIONS - Start Here

Service lines grand rounds is a quarterly CME program, providing service lines a platform to introduce their leadership, highlight specialty educational updates relevant to all (or most) physicians and providers, quality initiatives that may affect other service lines or be modeled by other service lines, and resources available within the service line that may be relevant to a broad audience.

1. Discuss the role of incretin hormones in metabolic regulation and how GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists impact obesity treatment.
2. Review the pharmacological mechanisms of GLP-1RAs and dual GLP-1/GIP receptor agonists, and compare their effects on metabolism, weight loss, and other metabolic parameters.
3. Identify the available GLP-1 receptor agonists and dual receptor agonists, including agents like semaglutide and tirzepatide, and understand dosing strategies, titration schedules, and routes of administration.
4. Determine the safety profile and side effects associated with GLP-1RAs and dual GLP-1/GIP receptor agonists, including common adverse effects and rare but serious concerns like pancreatitis and thyroid C-cell tumors.
5. Identify ideal candidates for incretin-based therapies, taking into account contraindications, precautions, and special considerations for populations such as those with diabetes or cardiovascular disease.

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

Thursday, March 13, 2025, 12:00 AM - Monday, March 13, 2028, 11:59 PM

Accreditation Statement: WellSpan Health is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. 

Credit Designation: WellSpan Health designates this Enduring Material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All faculty participating in continuing medical education programs sponsored by WellSpan Health are expected to disclosure to the program audience whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s).

Mitigation of Relevant Financial Relationships

WellSpan Health CME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.